Open AccessA Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1
Author(s) -
Gaetano Ciancio,
George W. Burke,
Jeffrey J. Gaynor,
Manuel Carreño,
Robert Cirocco,
James M. Mathew,
Adela Mattiazzi,
Tatiana Cordovilla,
David Roth,
Warren Kupin,
Anne Rosén,
Violet Esquenazi,
Andreas G. Tzakis,
Joshua Miller
Publication year - 2005
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000165847.05787.08
Subject(s) - tacrolimus , thymoglobulin , medicine , daclizumab , immunosuppression , calcineurin , methylprednisolone , nephrotoxicity , dosing , transplantation , gastroenterology , alemtuzumab , urology , kidney transplantation , group b , randomized controlled trial , kidney
New trends in immunosuppression in clinical transplantation include the use of antibody induction agents in protocols that emphasize reduction or avoidance of steroids and calcineurin inhibitors.